Drug Trial Radar · NCT06489548
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
16
Planned (sponsor's estimate)
Start
Sep 16, 2025
Primary completion
Jun 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Brigham and Women's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tiziana Life Sciences LTD
- First posted
- Jul 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase 2a study will research the safety and tolerability of Foralumab, a human anti-CD3 antibody. An antibody is a molecule secreted by the immune system. These molecules are created to identify a specific pathogen. Previous data on experimental mice has suggested that Foralumab increases the immune system activity in the brain to reduce the inflammation of microglia, the brain's main immune cells. This combination of increased immune reactivity and less microglia inflammation may improve the immune response throughout the brain. Alzheimer's disease and other forms of dementia are characteristically known for the build-up of certain proteins in the brain. This trial will evaluate whether nasal Foralumab can improve cognition in participants with mild cognitive impairment due to early Alzheimer's or dementia. The trial will ask participants to administer Foralumab nasally three times a week for eight weeks. The administration will occur intermittently, with breaks between each dosing cycle. Participants will also receive brain scans (Amyloid PET and MRI), undergo cognitive testing, blood draws, and physical, neurological, and nasal exams. Volunteers are expected to remain in the trial for six months.
Conditions
- Dementia
- Alzheimers Disease
- Mild Cognitive Impairment Due to Alzheimer's Disease
Interventions
Foralumab TZLS-401 50 µgDrug
Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 50 µg vs. placebo.
Foralumab TZLS-401 100 µgDrug
Foralumab is a nasal anti-CD3 antibody. It will be administered in doses of 100 µg vs. placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of adverse events in drug versus placebo groups.Time frame: From baseline to the end of study, up to 20 weeks.
- Assessment of microglial function via PET scan using the ligand [18F]PBR06Time frame: From baseline to end of study, up to 20 weeks.
- Measure the effect of foralumab on the ratio of CD4/CD8 memory/naïve T cells biomarkers in bloodTime frame: From baseline to the end of treatment, up to 12 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Center for Alzheimer Research and Treatment, Brigham and Women's Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.